Evidence map›Paper›PMID 22820528›Full record

ReviewAdvanced drug delivery reviews2012

Personalized nanomedicine advancements for stem cell tracking.

Miroslaw Janowski, Jeff W M Bulte, Piotr Walczak

Abstract readReview
In one paragraph

Review in Advanced drug delivery reviews, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Basic and Preclinical Research for Personalized Medicine.Journal of personalized medicine · 2021
    Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Pre- and postmortem imaging of transplanted cells.International journal of nanomedicine · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Miroslaw JanowskiRussell H. Morgan Department of Radiology and Radiological Science, Division of MR Research, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Jeff W M Bulte
Piotr Walczak

Funding

ValidationU54CA151838 · NCI · JOHNS HOPKINS UNIVERSITY · PI WANG, TZA-HUEI JEFF · 2010 to 2014
$11.9M
MR Tracking of Magnetically Labeled Stem Cells in CNSR01NS045062 · NINDS · JOHNS HOPKINS UNIVERSITY · PI BULTE, JEFF W. · 2003 to 2013
$4.4M
Efficient Targeting of Therapeutic Cells in Stroke and EAER01NS076573 · NINDS · JOHNS HOPKINS UNIVERSITY · PI WALCZAK, PIOTR · 2012 to 2016
$1.8M
Developing MPI for Non-Invasive and Quantitative Imaging of Stem CellsR01DA026299 · NIDA · JOHNS HOPKINS UNIVERSITY · PI BULTE, JEFF W. · 2008 to 2011
$1.3M
NCI NIH HHS U54 CA151838NIDA NIH HHS R01 DA026299NINDS NIH HHS 2R01 NS045062NINDS NIH HHS R01 NS045062NINDS NIH HHS R01 NS076573
6 · The paper itself

Abstract

Recent technological developments in biomedicine have facilitated the generation of data on the anatomical, physiological and molecular level for individual patients and thus introduces opportunity for therapy to be personalized in an unprecedented fashion. Generation of patient-specific stem cells exemplifies the efforts toward this new approach. Cell-based therapy is a highly promising treatment paradigm; however, due to the lack of consistent and unbiased data about the fate of stem cells in vivo, interpretation of therapeutic effects remains challenging hampering the progress in this field. The advent of nanotechnology with a wide palette of inorganic and organic nanostructures has expanded the arsenal of methods for tracking transplanted stem cells. The diversity of nanomaterials has revolutionized personalized nanomedicine and enables individualized tailoring of stem cell labeling materials for the specific needs of each patient. The successful implementation of stem cell tracking will likely be a significant driving force that will contribute to the further development of nanotheranostics. The purpose of this review is to emphasize the role of cell tracking using currently available nanoparticles.

Indexed as

Cell TrackingNanomedicinePrecision MedicineStem CellsAnimalsHumansNanoparticles

Identifiers

PMID22820528
PMCPMC3477295

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.